Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

Summary

This is a 96-week extension study of open-label simufilam 100 mg b.i.d. for mild-to-moderate Alzheimer's disease subjects who completed the Phase 2 study, PTI-125-04. The study will evaluate safety and long-term treatment. Safety will be assessed by AE monitoring, clinical labs, urinalysis, vital signs, ECGs, and C-SSRS.

Timeline

Start

2022-05-12

Primary completion

2024-12-31

Completion

2024-12-31

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision”

Drugs

Indications